# R4N PHARMA_V1 — Gate G6.43 Global Generics Momentum Parent-Contract / Benchmark Evidence Sufficiency Deferral Gate V1

**Status:** PROPOSAL ONLY / NOT ACTIVE  
**Primary subprofile:** `GLOBAL_GENERICS`  
**Canonical dimension:** `MOMENTUM`

## Purpose

G6.43 records that the Global Generics Momentum evidence identity is valid, but the prerequisites for numeric scoring are not established.

This is a fail-closed deferral.

## Current blockers

- Dedicated Pharma parent Momentum contract not established.
- Approved Pharma benchmark not established.
- Global Generics Momentum calibration set not established.
- Absolute-momentum band evidence not established.
- Relative-strength band evidence not established.
- Component-weight evidence not established.
- Final aggregation not established.

Therefore:

`dedicatedPharmaParentMomentumContractAvailable = false`

`approvedPharmaBenchmarkAvailable = false`

`numericMomentumCurveReady = false`

`wholeMomentumDimensionReady = false`

`deferralRequired = true`

## What remains valid

The evidence identity from G6.42 remains valid:

- `PRICE_MOMENTUM_12M`
- `PRICE_MOMENTUM_6M`
- `RELATIVE_STRENGTH_12M`
- raw authority: `MARKET_PRICE_HISTORY`
- derived evidence store: `MARKET_METRIC_OBSERVATIONS`
- absolute momentum definition: `CLOSE_TO_CLOSE_RETURN_WITH_14_DAY_LOOKBACK_TOLERANCE`
- relative strength definition: `STOCK_RETURN_MINUS_APPROVED_BENCHMARK_RETURN`

## What remains prohibited

- BANK_NBFC pilot as fallback.
- NIFTY BANK as Pharma benchmark by analogy.
- provider technical score as Momentum authority.
- fabricated Pharma benchmark.
- fabricated absolute-momentum or relative-strength bands.
- missing relative strength becoming neutral.
- hidden reweighting around a missing relative-strength component.

## Regulatory / Market Risk status

G6.24–G6.29 remain authoritative and are not reopened.

The Global Generics Risk slice remains explicitly incomplete/fail-closed.

## Safety boundary

- dedicated Pharma parent Momentum contract: **NO**
- approved Pharma benchmark: **NO**
- BANK fallback: **NO**
- Global Generics Momentum calibration: **NO**
- numeric Momentum curve: **NO**
- whole Momentum dimension ready: **NO**
- score execution: **NO**
- persistence: **NO**
- production mutation: **NO**
- deployment: **NO**
- PR #101 merge: **NO**

## Next step

After validation, close the Global Generics Momentum slice as explicitly incomplete/fail-closed. Then perform a G6 Global Generics coverage review to identify whether any canonical family still lacks an explicit validated outcome before moving toward G7.
